Clinical Trial: Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07543783) titled 'Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC' on April 03.

Brief Summary: his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Eligible participants will receive TACE followed by HAIC (oxaliplatin, leucovorin, and fluorouracil) and subsequent intravenous a...